PrEP at a Syringe Services Program

• Status: Not yet recruiting
• Trial end date: 2023-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if providing participants with pre-exposure prophylaxis (PrEP) medicine right away at the IDEA Exchange will help participants remain in HIV negative.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Miami
• Treatments: Emtricitabine tenofovir alafenamide

Criteria

Inclusion Criteria:

1. over the age of 18

2. speak either English or Spanish

3. ability to provide informed consent

4. currently enrolled in the syringe services program

5. have a negative HIV rapid test result

6. estimated creatinine clearance > 30 ml/minute

Exclusion Criteria:

1. do not meet the above criteria of inclusion

2. decline to participate

3. test positive for HIV via rapid test

4. are pregnant or plan on becoming pregnant

5. have symptoms acute HIV.

6. Any other comorbidities that at the discretion of the investigator would prevent the participant from participating in the study.